Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Vaccinazione di cellule tumorali allogeniche con Cytoxan metronomico orale in pazienti con neuroblastoma ad alto rischio (ATOMIC)

30 settembre 2026 aggiornato da: Helen Heslop, Baylor College of Medicine

Uno studio di fase I/II che utilizza la vaccinazione di cellule tumorali allogeniche con Cytoxan metronomico orale in pazienti con neuroblastoma ad alto rischio (ATOMIC)

Neuroblastoma is the second most common solid tumor seen in children, but causes approximately 15% of childhood cancer deaths each year. Patients with high-risk disease require treatment with a combination of chemotherapy, surgery, radiation, and stem cell transplant; however, many will have their disease come back within 3 years. Due to this high rate of relapse, this study is being done to investigate an experimental treatment option for children whose disease has returned.

This clinical trial is for patients with neuroblastoma that has either come back after treatment or never went away in the first place. A series of immunizations will be administered using a tumor vaccine and add low-dose chemotherapy to be taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy. Daily low-dose chemotherapy, also know as metronomic chemotherapy, works by attacking the blood vessels that allow tumors to grow. Using metronomic doses of a drug called cytoxan can also decrease T regulatory cells, a specific type of cell that tumors use to hide from the immune system.

The purpose of this study is to test the safety and anti-tumor effect of the tumor cell vaccination plus low dose, metronomic chemotherapy in treating patients with relapsed/refractory neuroblastoma.

Panoramica dello studio

Descrizione dettagliata

WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 days after starting oral cytoxan. The 2nd to 4th injections will be given approximately every 14 days after the previous vaccine. During this time, the patient will be taking oral cytoxan once a day except on the day of and 4 days following the vaccine. Two to 3 weeks after the 4th vaccine, the patient will have a complete evaluation of their disease. If the scans and lab tests show that the patient has not had any serious side-effects, they will be eligible to receive 4 additional vaccinations given at 3 week intervals. The disease will be re-evaluated again after vaccine numbers 6 and 8. If the patient is able to complete the entire study, they will have received a total of 8 vaccinations and the last dose of oral cytoxan will be 1 month after the 8th vaccination. Total time duration for participating in this study is 15 years (treatment portion within year 1 and follow up during years 2-15).

Neuroblastoma vaccinations are given like many other vaccines. They will be given subcutaneously. The injections will be 1/10th of a teaspoon.

MEDICAL TESTS BEFORE STARTING TREATMENT:

Before starting low dose chemotherapy plus oral cytoxan, patients will receive a series of standard medical tests:

  • Physical exam
  • Blood tests to measure blood cells, blood salts, kidney and liver function
  • Measurements of their disease (CT or MRI of the primary tumor site and any locations of tumor spread; MIBG or Bone scan; Chest X-ray if they did not have a CT of the chest; and bone marrow studies if the patient has known bone marrow disease)
  • Baseline testing of immune function
  • Pregnancy testing will be performed on females of child bearing age

MEDICAL TESTS DURING AND AFTER TREATMENT:

Prior to each vaccine dose, the patient will receive:

  • Physical exam
  • Blood tests to measure blood cells, blood salts, kidney and liver function
  • Measurements of the disease (CT or MRI of the primary tumor site and any locations of tumor spread; MIBG or Bone scan; Chest X-ray if they did not have a CT of the chest; and bone marrow studies if they have known bone marrow disease) after the 4th, 6th and 8th vaccine.
  • Testing of immune function
  • Pregnancy testing will be performed again on females of child bearing age prior to the 5th vaccine

To learn more about the way the vaccine is stimulating the immune cells, we will collect blood prior to each vaccination and at scheduled time points until 3 months after the last vaccine treatment. The total amount of blood to be collected on any day is no more than 2 ounces, but will depend upon the weight. This volume is considered safe in teens and adults, but may be decreased if the patient is anemic. On days when the patient receives the vaccine, blood will be taken before the cells are given.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

11

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

INCLUSION CRITERIA:

  • Histologically proven high risk neuroblastoma in first or subsequent relapse or with primary refractory disease or inability to complete standard therapy
  • Age less than 21 at time of initial diagnosis
  • Life expectancy 12 weeks or greater
  • Karnofsky or Lansky score of 50 or greater
  • Platelet count of 50,000/ul or greater
  • ANC greater than 750/ul
  • Alk Phos level less than 2.5 x upper limit of normal
  • Bilirubin less than 2x normal
  • AST less than 3x normal
  • Hgb 8.0 or greater
  • Creatinine 2 x ULN or less OR GFR greater than 40 ml/min/1.73 m2
  • Patient has recovered from last chemotherapy or investigational therapy prior to study enrollment
  • Women of child-bearing potential must not be pregnant and take/use effective birth control while participating in the study.

EXCLUSION CRITERIA:

  • Due to the unknown effects of this therapy on a fetus, pregnant women will be excluded from this research
  • Women who are breast-feeding
  • Known HIV positive subjects since treatment may be immunosuppressive
  • Severe intercurrent infection or uncontrolled condition including, but not limited to ongoing or active infection, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Previous use of oral cytoxan for more than 2 consecutive months within the last 6 months
  • Patients currently receiving any investigational agents or have received any tumor vaccines within the previous six months
  • Patients, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment Plan

Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)

1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.

Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.

Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol.

Altri nomi:
  • SKNLP con modifica genetica. SJNB-JF-IL2 e SJNB-JF-LTN neurobl. cellule

Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.

Altri nomi:
  • Ciclofosfamide

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Lasso di tempo: week 30

Phase I Primary Objective: Evaluate the safety of fixed dose oral cytoxan administered metronomically to coincide with repeated immunizations of gene-modified, IL-2/lymphotactin secreting SJNB-JF-IL2 and SJNB-JF-LTN cells co-administered with unmodified SKNLP neuroblastoma cell lines in patients with a history of relapsed/refractory high-risk neuroblastoma.

week 30

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participants with T-cell changes as a Measure of Immune Response
Lasso di tempo: 15 years

Phase I Secondary Objective: Evaluate the immune response to combination metronomic chemotherapy and allogeneic tumor cell immunizations.

15 years
Number of Participants with Disease Progression as a Measure of Efficacy
Lasso di tempo: 10 weeks

Phase II Primary Objective: Evaluate time to progression after administration of combination metronomic chemotherapy and allogeneic tumor cell immunizations in patients with a history of relapsed/refractory high-risk neuroblastoma.

10 weeks

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Analysis of Immunologic Measurements
Lasso di tempo: 15 years

Phase II Secondary Objectives:

  1. Evaluate changes in T regulatory cell absolute number, percentages, and suppressive function after the use of metronomic low-dose oral cytoxan with allogeneic neuroblastoma tumor cell immunizations.
  2. Evaluate the alterations in angiogenic biomarkers related to fixed dose oral cytoxan and repeated immunizations with allogeneic tumor cell immunizations.
15 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Helen Heslop, MD, Baylor College of Medicine
  • Investigatore principale: Malcolm Brenner, MD, The Methodist Hospital Research Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 settembre 2010

Completamento primario (Effettivo)

1 luglio 2012

Completamento dello studio (Stimato)

1 giugno 2027

Date di iscrizione allo studio

Primo inviato

16 agosto 2010

Primo inviato che soddisfa i criteri di controllo qualità

30 agosto 2010

Primo Inserito (Stimato)

1 settembre 2010

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi